about
Targeting the Bcl-2 family for cancer therapyTargeting Mcl-1 for the therapy of cancerCisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cellsTargeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cellsMechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting AktInhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant gliomaPERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells.Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1.FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells.A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapyMelanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress.IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR.Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics.Emerging strategies for the early detection and prevention of head and neck squamous cell cancerAstrocyte elevated gene-1: a novel target for human glioma therapy.Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokineOncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity.Autophagy switches to apoptosis in prostate cancer cells infected with melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24)Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cellsmda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer.Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline.MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanomaSelected approaches for rational drug design and high throughput screening to identify anti-cancer moleculesNovel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction.MDA-9/syntenin: a positive gatekeeper of melanoma metastasis.Silk sericin protein of tropical tasar silkworm inhibits UVB-induced apoptosis in human skin keratinocytes.Purification and biochemical characterization of a 70 kDa sericin from tropical tasar silkworm, Antheraea mylitta.mda-7/IL-24 expression inhibits breast cancer through upregulation of growth arrest-specific gene 3 (gas3) and disruption of β1 integrin function.Chemoprevention gene therapy (CGT): novel combinatorial approach for preventing and treating pancreatic cancer.AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells.ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis.BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancerDDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m6A-demethylation of FOXM1 and NANOG
P50
Q26866936-223C0B83-A6C6-44F6-83E5-E184ADFD4200Q27011870-89C1644A-D1E9-4510-865E-3D7D84D82E96Q33613377-A35C8C22-8429-42E4-81C0-E88F78AC8F72Q33775637-5C689960-98DA-4E9E-BA93-CCD345C45DD9Q33870560-65B0CE7C-B9AC-499A-8B69-C5C70EBEBE41Q33877402-D5AE652A-E4F1-452A-92DD-9F46BC2A5DA0Q33930115-4752C9B4-4601-4C78-88A4-B62615CD1B5DQ33931451-588E02CE-EBCC-4EB2-BF3B-F8604F9E464FQ34119653-AA735F79-9FCC-4943-9C52-965BCC1A8939Q34127893-E8E9044D-9718-4CE0-9B24-31A7252BCB02Q34341900-D6141F55-D00A-48DC-BA64-96CE9D3E146DQ34359570-6798F738-A1E2-4DED-854A-93E658CC3336Q35037290-5651F2FE-FA75-4AA5-9CE9-66620608E00DQ35087565-1C8A3668-02BE-4C7A-A3F8-CBE0BFE3AC22Q35172778-3BE3E324-E1A2-4A09-A9FF-B4FE5C87D09BQ35190515-C2ABAFE8-3878-41AF-9AE0-70458A07D19AQ35209685-BAB1286D-C7A6-4BC8-B85E-F6DD59D78F7FQ35349743-FC64D865-1778-4833-9EAB-DE357F3895D3Q35534105-04341493-E194-4371-B701-32B753DE5A38Q35545634-725E40B1-004F-4771-8D07-D503D6B3B178Q35587169-09D15D0A-045B-4C17-BD3D-466A41B5169DQ35587172-316BC801-2894-4B7E-9960-293BEA75C6C7Q35676278-B10C4ABD-436B-4880-99D7-2360B3E2CD88Q36545071-8706F449-C559-4F7B-B7FD-55D3A24FE5FBQ37149641-243D3BEB-0B5C-4979-A565-55305927EA1AQ37561261-2057726D-71CB-4C72-88D1-7CC7F02DC745Q37971509-9FF5EB85-CBC8-4812-8C52-75B450FC02AAQ38962612-AAC41AFB-855A-438A-A4EA-C3617BA13D95Q38962615-0DB11CA8-C180-4367-8142-3B34F0C54F25Q39184021-F558B8E6-A5EB-42A2-937E-1C22D3693D2BQ39243757-291D9086-B13C-49B6-BB11-0A90F23BA9BEQ39291133-4FF0B4E6-B090-4565-B460-2647EFA9E887Q39674592-0D0D7D7B-0D47-492F-8D77-7B00103D80B2Q39770856-25D68C14-EC8C-4491-916C-B5594C4CF2E9Q40886681-61BDE703-A65C-4CE2-B219-3B07BC226713Q57173514-0E0EBEE0-F0E4-4208-A5C6-34E651EC443EQ92892994-00952BE7-4046-4894-A12D-3A49470D53BF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rupesh Dash
@ast
Rupesh Dash
@en
Rupesh Dash
@es
Rupesh Dash
@nl
Rupesh Dash
@sl
type
label
Rupesh Dash
@ast
Rupesh Dash
@en
Rupesh Dash
@es
Rupesh Dash
@nl
Rupesh Dash
@sl
prefLabel
Rupesh Dash
@ast
Rupesh Dash
@en
Rupesh Dash
@es
Rupesh Dash
@nl
Rupesh Dash
@sl
P106
P1153
35168986900
P31
P496
0000-0001-5740-7053